“Rare ingredients with health-promoting properties are effective only if they are safe and widely available to those who could benefit from them. Jing-Ke Weng, co-founder of DoubleRainbow Biosciences (Double Rainbow) said: “Gastrogin is a powerful natural pain reliever and we are excited about its potential to improve human health.”na
It is the Massachusetts-based company’s second bioengineered ingredient and was introduced through its wholly-owned subsidiary, Landkind. “World’s First Sustainable Dietary Supplement Company”Its first ingredient LK-01 is pure salidroside, a traditionally plant-derived adaptogen Rhodiola rosealaunched last summer, to supplement cognitive and motor skills.
Possibility of gastrodinna
According to ResearchandMarkets, the global pain reliever industry is expected to reach $50.6 billion by 2030, and Double Rainbow expects demand for gastrogin in that market to grow significantly over the next five years.
“With high demand for new personalized therapies to better manage or prevent the development of chronic pain and opioid abuse, Gastrogin is poised to enter new markets around the world.”The company said in a statement.
Isolated from rare tubers gastrodia erata This perennial plant compound has been used in Asia for over 2,000 years to treat spasms, tetanus, headaches, epilepsy, dizziness, numbness, rheumatism and paralysis. Known as Tianma in traditional Chinese medicine. “Eliminates internal winds, stops spasms, calms liver, suppresses yang”Relieves dizziness and headaches, according to the Asante Academy of Chinese Medicine.
“Double Rainbow chose to focus on gastrogin as the second in its pipeline because it is a natural pain reliever with a wide range of potential therapeutic uses.” Landkind’s Vice President of Corporate Strategy and Chief Brand Officer, Grant Smith, told NutraIngredients-USA:
Modern clinical trials range from protecting against chronic inflammatory pain and treating migraines, vertigo and Tourette’s system to preventing cognitive decline associated with cardiopulmonary bypass and restoring neurological function after spinal cord injury. , has been explored for its potential in a range of uses.
Harmony and Prism: more to comena
Through its nature-identical biosynthetic platform Harmony and enzyme modification platform Prism, Double Rainbow seeks to harness advances in genomics, metabolomics, and synthetic biology to provide sustainable alternatives to plant extraction or chemosynthesis. is.
“Combining Double Rainbow’s technology will allow the team to modify the molecules as needed and optimize their pharmacodynamic properties through the Prism enzymatic glycosylation platform.”Mr Smith explained. “Precise glycosylation of Prism enables the creation of new molecular entities with potentially enhanced solubility, bioavailability and tissue specificity..”na
He said the company will pursue a strong preclinical and clinical research program to further validate the safety and health benefits of gastrogin alone and in potential combinations for pain relief and mental health. In addition, it plans to commercialize more than 12 pharmaceutical ingredients, including multiple combination LK-01 products, by 2025, and has partnered with Karai Pharmaceuticals to develop drugs for psychiatric and psychiatric disorders. Exploring biosynthetic kavalactones for substance use disorders. In nature, kava lactones are found in kava root, alpinia zermbet(getto).
“Among consumer health, the company will use our technology to reduce threats to rare or endangered plants, promote sustainable energy, higher levels of cognitive performance, and healthier lives. We see the greatest opportunity in offering Landkind products that accelerate aging.”Smith said.